{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:16:51Z","timestamp":1794359811569,"version":"4.9.0"},"reference-count":45,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"8","license":[{"start":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Efanesoctocog alfa (Altuviiio,TM Sanofi-SOBI) is a B domain-deleted single-chain Factor VIII (FVIII) connected to D\u2019D3 domain of von Willebrand Factor (vWF). Its ingenious design allows efanesoctocog alfa to operate independently of endogenous vWF and results in an outstanding 3-4 times longer half-life compared to standard and extended half-life (EHL) FVIII products. The prolonged half-life ensures sustained high levels of factor activity, maintaining normal to near-normal ranges for the majority of the week, facilitating the convenience of once-weekly administration. Efanesoctocog alfa received regulatory approval in 2023 for application in both adults and children with inherited hemophilia A in the United States and Japan. Its sanctioned use encompasses both prophylaxis and \u2018on demand\u2019 treatment for bleeding episodes. The European Medicines Agency (EMA) is currently undertaking a comprehensive review of Altuviiio. TM This comprehensive review focuses on the immunological profile of efanesoctocog alfa, a highly sophisticated new class of EHL FVIII molecule. The integration of the vWF D\u2019D3 domain, XTEN polypeptides, and potential regulatory T-cell epitopes within various segments of efanesoctocog alfa collectively serves as a mitigating factor against the development of a neutralizing T-cell-mediated immune response. We hypothesize that such distinctive attribute may significantly reduce the risk of neutralizing antibodies, particularly in previously untreated patients. The discussion extends beyond regulatory approval to encompass the preclinical and clinical development of efanesoctocog alfa, including considerations for laboratory monitoring. The review also highlights areas that warrant further investigation to deepen our understanding of this groundbreaking therapeutic agent.<\/jats:p>","DOI":"10.3324\/haematol.2023.284498","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T03:26:29Z","timestamp":1707967589000},"page":"2436-2444","source":"Crossref","is-referenced-by-count":24,"title":["Efanesoctocog alfa: the renaissance of Factor VIII replacement therapy"],"prefix":"10.3324","volume":"109","author":[{"given":"Yesim","family":"Dargaud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Leuci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra Reyes","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Lacroix-Desmazes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,2,15]]},"reference":[{"key":"63903","doi-asserted-by":"crossref","unstructured":"Mannucci PM, Franchini M. Haematology clinic: haemophilia A. Hematology. 2014; 19(3):181-182.","DOI":"10.1179\/1024533214Z.000000000262"},{"key":"63904","doi-asserted-by":"crossref","unstructured":"Lafeber FP, Miossec P, Valentino LA. Physiopathology of haemophilic arthropathy. Haemophilia. 2008; 14(Suppl 4):3-9.","DOI":"10.1111\/j.1365-2516.2008.01732.x"},{"key":"63905","doi-asserted-by":"crossref","unstructured":"Oldenburg J. Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. Blood. 2015; 125(13):2038-2044.","DOI":"10.1182\/blood-2015-01-528414"},{"key":"63906","doi-asserted-by":"crossref","unstructured":"Mannucci PM. Hemophilia treatment innovation: 50 years of progress and more to come. J Thromb Haemost. 2023; 21(3):403-412.","DOI":"10.1016\/j.jtha.2022.12.029"},{"key":"63907","doi-asserted-by":"crossref","unstructured":"Gualtierotti R, Solimeno LP, Peyvandi F. Hemophilic arthropathy: current knowledge and future perspectives. J Thromb Haemost. 2021; 19(9):2112-2121.","DOI":"10.1111\/jth.15444"},{"key":"63908","doi-asserted-by":"crossref","unstructured":"Peyvandi F, Mannucci PM, Garagiola I. A randomized trial of Factor VIII and neutralizing antibodies in hemophilia A. New Engl J Med. 2016; 374(21):2054-2064.","DOI":"10.1056\/NEJMoa1516437"},{"key":"63909","doi-asserted-by":"crossref","unstructured":"Gouw SC, van der Bom JG, Ljung R. Factor VIII products and inhibitor development in severe haemophilia A. N Engl J Med. 2013; 368(3):231-239.","DOI":"10.1056\/NEJMoa1208024"},{"key":"63910","doi-asserted-by":"crossref","unstructured":"Fischer K, Carcao M, Male C. Different inhibitor incidence for individual factor VIII concentrates in 1076 previously untreated patients with severe hemophilia A: data from the PedNet cohort. J Thromb Haemost. 2023; 21(3):700-703.","DOI":"10.1016\/j.jtha.2022.11.020"},{"key":"63911","doi-asserted-by":"crossref","unstructured":"Brod M, Bushnell DM, Neergaard JS, Waldman LT, Busk AK. Understanding treatment burden in hemophilia : development and validation of the Hemophilia Treatment Experience Measure (Hemo-TEM). J Patient Rep Outcomes. 2023; 7(1):17.","DOI":"10.1186\/s41687-023-00550-6"},{"key":"63912","doi-asserted-by":"crossref","unstructured":"Pipe SW, Montgomery RR, Pratt KP, Lenting PJ, Lillicrap D. Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A. Blood. 2016; 128(16):2007-2016.","DOI":"10.1182\/blood-2016-04-713289"},{"key":"63913","doi-asserted-by":"crossref","unstructured":"Vlot AJ, Koppelman SJ, van den Berg MH, Bouma BN, Sixma JJ. The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor. Blood. 1995; 85(11):3150-3157.","DOI":"10.1182\/blood.V85.11.3150.bloodjournal85113150"},{"key":"63914","doi-asserted-by":"crossref","unstructured":"Carcao MD, Chelle P, Clarke E. Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: is there a difference?. J Thromb Haemost. 2019; 17(7):1085-1096.","DOI":"10.1111\/jth.14469"},{"key":"63915","doi-asserted-by":"crossref","unstructured":"van der Flier A, Liu Z, Tan S. FcRn rescues recombinant Factor VIII Fc fusion protein from a VWF independent FVIII clearance pathway in mouse hepatocytes. PLoS One. 2015; 10(4):e0124930.","DOI":"10.1371\/journal.pone.0124930"},{"key":"63916","doi-asserted-by":"crossref","unstructured":"Mazurier C, Goudemand J, Hilbert L, Caron C, Fressinaud E, Meyer D. Type 2N von Willebrand disease: clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology. Best Pract Res Clin Haematol. 2001; 14(2):337-347.","DOI":"10.1053\/beha.2001.0138"},{"key":"63917","doi-asserted-by":"crossref","unstructured":"Yee A, Gildersleeve RD, Gu S. A von Willebrand factor fragment containing the D\u2019D3 domains is sufficient to stabilize coagulation factor VIII in mice. Blood. 2014; 124(3):445-452.","DOI":"10.1182\/blood-2013-11-540534"},{"key":"63918","doi-asserted-by":"crossref","unstructured":"Fuller JR, Knockenhauer KE, Leksa NC, Peters RT, Batchelor JD. Molecular determinants of the factor VIII\/von Willebrand factor complex revealed by BIVV001 cryo-electron microscopy. Blood. 2021; 137(21):2970-2980.","DOI":"10.1182\/blood.2020009197"},{"key":"63919","doi-asserted-by":"crossref","unstructured":"Schellenberger V, Wang CW, Geething NC. A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nat Biotechnol. 2009; 27(12):1186-1190.","DOI":"10.1038\/nbt.1588"},{"key":"63920","doi-asserted-by":"crossref","unstructured":"Seth Chhabra E, Liu T, Kulman J. BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice. Blood. 2020; 135(17):1484-1496.","DOI":"10.1182\/blood.2019001292"},{"key":"63921","doi-asserted-by":"crossref","unstructured":"Demers M, Aleman MM, Kistanova E, Peters R, Salas J, Seth Chhabra E. Efanesoctocog alfa elicits functional clot formation that is indistinguishable to that of recombinant factor VIII. J Thromb Haemost. 2022; 20(7):1674-1683.","DOI":"10.1111\/jth.15741"},{"key":"63922","doi-asserted-by":"crossref","unstructured":"Konkle BA, Shapiro AD, Quon DV. BIVV001 fusion protein as Factor VIII replacement therapy for hemophilia A. N Engl J Med. 2020; 383(11):1018-1027.","DOI":"10.1056\/NEJMoa2002699"},{"key":"63923","doi-asserted-by":"crossref","unstructured":"Lissitchkov T, Willemze A, Katragadda S, Rice K, Poloskey S, Benson C. Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study. Blood Adv. 2022; 6(4):1089-1094.","DOI":"10.1182\/bloodadvances.2021006119"},{"key":"63924","doi-asserted-by":"crossref","unstructured":"von Drygalski A, Chowdary P, Kulkarni R. Efanesoctocog alfa prophylaxis for patients with severe hemophilia A. N Engl J Med. 2023; 388(4):310-318.","DOI":"10.1056\/NEJMoa2209226"},{"key":"63925","unstructured":"Wilson A, Nemes L, Quon DV. Efanesoctocog alfa prophylaxis improves health-related quality of life in patients with hemophilia A: results from the XTEND-1 phase 3 study. Haemophilia. 2023; 29(Suppl 1):105."},{"key":"63926","doi-asserted-by":"crossref","unstructured":"Wilson A, Kragh N, DiBenedetti D. Patient experience with efanesoctoocg alfa: results from the xtend-1 phase 3 clinical trial exit interviews in patients with severe haemophilia A. Haemophilia. 2023; 29(Suppl 1):137.","DOI":"10.1016\/j.clinthera.2024.09.010"},{"key":"63927","doi-asserted-by":"crossref","unstructured":"Malec L, Peyvandi F, Chan A. Efanesoctocog alfa prophylaxis for previously treated patients &lt;12 years of age with severe hemophilia A. Res Pract Thromb Haemost. 2023; 7(Suppl 2):1-2.","DOI":"10.1016\/j.rpth.2023.100288"},{"key":"63928","doi-asserted-by":"crossref","unstructured":"Malec L, Dunn A, Carcao M. Treatment of bleeding episodes with efanesoctoctocog alfa in children with severe hemophilia A in XTEND-Kids phase 3 Study. Blood. 2023; 142(Suppl 1):3993.","DOI":"10.1182\/blood-2023-188739"},{"key":"63929","unstructured":"Klamroth R, von Drygalski A, Hermans C. Perioperative management with efanesoctocog alfa in patients with haemophilia A in the phase 3 XTEND-1 study. Haemophilia. 2023; 29(Suppl 1):87-88."},{"key":"63930","doi-asserted-by":"crossref","unstructured":"Kitchen S, Tiefenbacher S, Gosselin R. Factor activity assays for monitoring extended half-life FVIII and FIX replacement therapies. Sem Thromb Haemost. 2017; 43(3):331-337.","DOI":"10.1055\/s-0037-1598058"},{"key":"63931","doi-asserted-by":"crossref","unstructured":"Pipe S, Sadeghi-Khomami A, Konkle BA. A global comparative field study to evaluate the factor VIII activity of efanesoctocog alfa by one-stage clotting and chromogenic substrate assays at clinical haemostasis laboratories. Haemophilia. 2024; 30(1):214-223.","DOI":"10.1111\/hae.14831"},{"key":"63932","doi-asserted-by":"crossref","unstructured":"Hermans C, Mancuso ME, Nolan B, Pasi KJ. Recombinant factor VIII Fc for the treatment of haemophilia A. Eur J Haematol. 2021; 106(6):745-761.","DOI":"10.1111\/ejh.13610"},{"key":"63933","doi-asserted-by":"crossref","unstructured":"Mahlangu J, Powell jS, Ragni MV. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014; 123(3):317-325.","DOI":"10.1182\/blood-2013-10-529974"},{"key":"63934","doi-asserted-by":"crossref","unstructured":"K\u00f6nigs C, Ozelo MC, Dunn A. First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results. Blood. 2022; 139(26):3699-3707.","DOI":"10.1182\/blood.2021013563"},{"key":"63935","doi-asserted-by":"crossref","unstructured":"Dasgupta S, Navarrete AM, Bayry J. A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes. Proc Natl Acad Sci USA. 2007; 104(21):8965-8970.","DOI":"10.1073\/pnas.0702120104"},{"key":"63936","doi-asserted-by":"crossref","unstructured":"Gangadharan B, Ing M, Delignat S. The C1 and C2 domains of blood coagulation factor VIII mediate its endocytosis by dendritic cells. Haematologica. 2017; 102(2):271-281.","DOI":"10.3324\/haematol.2016.148502"},{"key":"63937","doi-asserted-by":"crossref","unstructured":"Delignat S, Rayes J, Dasgupta S. Removal of mannoseending glycan at Asn2118 abrogates FVIII presentation by human monocyte-derived dendritic cells. Front Immunol. 2020; 11:393.","DOI":"10.3389\/fimmu.2020.00393"},{"key":"63938","doi-asserted-by":"crossref","unstructured":"Delignat S, Dasgupta S, Andre S. Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A. Haematologica. 2007; 92(10):1423-1426.","DOI":"10.3324\/haematol.11438"},{"key":"63939","doi-asserted-by":"crossref","unstructured":"Swystun LL, Lai JD, Notley C. The endothelial cell receptor stabilin-2 regulates VWF-FVIII complex half-life and immunogenicity. J Clin Invest. 2018; 128(9):4057-4073.","DOI":"10.1172\/JCI96400"},{"key":"63940","doi-asserted-by":"crossref","unstructured":"De Groot AS, Moise L, McMurry JA. Activation of natural regulatory T cells by IgG Fc-derived peptide \u201cTregitopes.\u201d. Blood. 2008; 112(8):3303-3311.","DOI":"10.1182\/blood-2008-02-138073"},{"key":"63941","doi-asserted-by":"crossref","unstructured":"Moise L, Gutierrez AH, Bailey-Kellogg C. The two-faced T cell epitope: examining the host-microbe interface with JanusMatrix. Hum Vaccines Immunother. 2013; 9(7):1577-1586.","DOI":"10.4161\/hv.24615"},{"key":"63942","doi-asserted-by":"crossref","unstructured":"De Groot AS, Rosenberg AS, Miah SMS. Identification of a potent regulatory T cell epitope in factor V that modulates CD4+ and CD8+ memory T cell responses. Clin Immunol. 2021; 224:108661.","DOI":"10.1016\/j.clim.2020.108661"},{"key":"63943","doi-asserted-by":"crossref","unstructured":"Oleshko O, Vollack-Hesse N, Tiede A, Hegermann J, Curth U, Werwitzke S. von Willebrand factor modulates immune complexes and the recall response against factor VIII in a murine hemophilia A model. Blood Adv. 2023; 7(21):6771-6781.","DOI":"10.1182\/bloodadvances.2023010388"},{"key":"63944","unstructured":"Bioverative Therapeutics Inc. Efanesoctocog alfa US prescribing information. 2023. Publisher Full Text|"},{"key":"63945","doi-asserted-by":"crossref","unstructured":"Khawaji M, Akesson K, Berntorp E. Long-term prophylaxis in severe haemophilia seems to preserve bone mineral density. Haemophilia. 2009; 15(1):261-266.","DOI":"10.1111\/j.1365-2516.2008.01912.x"},{"key":"63946","doi-asserted-by":"crossref","unstructured":"Kiialainen A, Niggli M, Kempton CL. Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study. Haemophilia. 2022; 28(6):1033-1043.","DOI":"10.1111\/hae.14642"},{"key":"63947","doi-asserted-by":"crossref","unstructured":"Klamroth R, Bonner A, Gomez K. Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec versus extended half-life factor IX therapies for severe or moderately severe haemophilia B. Haemophilia. 2024; 30(1):75-86.","DOI":"10.1111\/hae.14882"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284498\/76616","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284498\/77330","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11450\/76616","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:43Z","timestamp":1794045943000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.284498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,15]]},"references-count":45,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.284498","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,15]]}}}